They speculate that DUSP6/MKP-3 might be required to prevent BrafV600E hyperactivation from triggering cell death via ERK1/2 downstream substrates and suggest that it might represent a synthetic lethal drug target in this subset of melanoma patients [165]. This evidence concerns the gene DUSP6 and melanoma.